MICROPORT NEURO (02172.HK): NuWismen Enters NMPA Green Path

NewTimeSpace News: On 24 September 2026, MicroPort NeuroScientific Corporation (stock code: 02172.HK) announced on a voluntary basis that NuWismen® Liquid Embolic Agent developed by the Group has passed the special review application for innovative medical devices of the National Medical Products Administration (NMPA) and entered the special review procedure (the "Green Path").

This selection marks the Group's eighth product to be included in the NMPA's special review for innovative medical devices, completing its product portfolio for the treatment of cerebral vascular malformations and further enhancing its ability to provide comprehensive interventional solutions across all scenarios involving cerebrovascular diseases. The announcement noted that cerebral vascular malformations include common lesions such as brain arteriovenous malformations (bAVM) and dural arteriovenous fistulas (dAVF); for complex lesions that are deeply located, involve functional areas, or are complicated by aneurysms or high-flow fistulas, interventional embolization is the first choice in clinical treatment and an important means of combined therapy.

The Group currently offers 29 neuro-interventional products covering major diseases such as aneurysms, stenosis and thrombus extraction. Including the newly selected product, eight of the Group's products have been included in the NMPA's Green Path; the remaining seven are Tubridge® Flow Diverter, Bridge® Rapamycin Target Eluting Vertebral Stent System, Tigertriever® Revascularization Device, Rebridge® Intracranial Stent, StraitPass® Disposable Aspiration Neuroendoscope Device, Nufairy™ Absorbable Coil and Artemis Dream® Self-Expanding Intracranial Rapamycin Eluting Stent System, three of which have already been launched commercially. The Company stated that there can be no assurance that NuWismen® Liquid Embolic Agent will eventually be successfully commercialized, and shareholders and potential investors should exercise caution when investing in the shares. In addition, trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 1 September 2026 and will remain suspended until further notice.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.